The Company
Aerie Pharmaceuticals is a privately held, clinical-stage biotechnology company
dedicated to the discovery and development of novel treatments for glaucoma.
All technology of the company is based on internal discovery R&D and is
protected by a strong IP portfolio. The US-based company is located in
Bridgewater, NJ and in Research Triangle Park, NC. Investors in Aerie are TPG
Biotech, Alta Partners, Clarus Ventures, Sofinnova Ventures and Osage
University Partners. In February 2011, the company closed a Series B financing
of $30 million.
Focused Strategy
Aerie is developing a diverse portfolio of proprietary molecules for
ophthalmic use from internal discovery, academia, and industry. In
addition, Aerie optimizes delivery of medications to ocular target tissues and
enhances patient compliance by developing novel, sustained drug delivery
solutions. Aerie’s management focuses on speed and efficiency across the
development process, while preserving the quality and integrity of the science.
Aerie’s business model has proven to be highly capital-efficient by investing
in unique internal core competencies, while outsourcing non-strategic
activities.
Specialized Tools
Aerie performs pre-clinical development of its technology in state-of-the-art
laboratories by mobilizing the experience and expertise of its talented
scientific staff. Our proven core competencies include ophthalmology, medicinal
chemistry, cell biology, and pharmacology. Our facilities allow us to
rapidly and efficiently screen new compounds and formulations.
Investors
The company has raised $61 million from current investors: Alta Partners,
Clarus Ventures, Osage University Partners, Sofinnova Ventures, and TPG
Biotech.
|
